Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Response01:28

Inflammatory Response

An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Complement System01:27

Complement System

The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a membrane...
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Antimicrobial Proteins01:23

Antimicrobial Proteins

Antimicrobial proteins are important components of the immune system. They aid the body in combating pathogens by either killing them directly or hindering their replication processes. Four main types of antimicrobial substances are interferons, the complement system, iron-binding proteins, and antimicrobial proteins.
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Surface-targeted complement modulation at biomedical interfaces.

Trends in pharmacological sciences·2026
Same author

Production and characterization of gigastasin, a leech-derived inhibitor of complement and coagulation pathways.

Scientific reports·2026
Same author

New Analogs of the Compstatin Family of Clinical Complement Inhibitors with Low Picomolar Target Affinity.

Journal of medicinal chemistry·2026
Same author

Drug transporter - enzyme crossroads: Does OATP2B1 shape Cyp3a-driven midazolam metabolism in rats?

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences·2025
Same author

Danicopan: complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria.

Trends in pharmacological sciences·2025
Same author

Insights Into Atorvastatin Pharmacokinetics in Rats Reveal Regulation of CYP3A1 by Humanization of SLCO2B1.

Pharmacology research & perspectives·2025

Related Experiment Video

Updated: May 12, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Complement in immune and inflammatory disorders: therapeutic interventions.

Daniel Ricklin1, John D Lambris

  • 1Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. ricklin@upenn.edu

Journal of Immunology (Baltimore, Md. : 1950)
|April 9, 2013
PubMed
Summary

Novel immunomodulatory strategies targeting the complement system offer new therapeutic avenues for inflammatory diseases. This review highlights promising complement-directed drugs and concepts for early intervention.

More Related Videos

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response
12:50

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response

Published on: September 15, 2017

Intravenous Endotoxin Challenge in Healthy Humans: An Experimental Platform to Investigate and Modulate Systemic Inflammation
07:48

Intravenous Endotoxin Challenge in Healthy Humans: An Experimental Platform to Investigate and Modulate Systemic Inflammation

Published on: May 16, 2016

Related Experiment Videos

Last Updated: May 12, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response
12:50

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response

Published on: September 15, 2017

Intravenous Endotoxin Challenge in Healthy Humans: An Experimental Platform to Investigate and Modulate Systemic Inflammation
07:48

Intravenous Endotoxin Challenge in Healthy Humans: An Experimental Platform to Investigate and Modulate Systemic Inflammation

Published on: May 16, 2016

Area of Science:

  • Immunology and Inflammation
  • Drug Discovery
  • Complement System Biology

Background:

  • Immune-inflammatory cross-talk underlies numerous diseases, driving demand for new therapies.
  • The complement system is a key regulator of immune and inflammatory responses, making it a critical therapeutic target.
  • Diverse complement-mediated pathologies necessitate a range of treatment strategies.

Purpose of the Study:

  • To review immunomodulatory strategies targeting the complement system.
  • To highlight promising complement-directed therapeutic concepts and candidate molecules.
  • To discuss the role of complement in inflammatory diseases and drug discovery.

Main Methods:

  • Literature review of complement-directed therapeutic strategies.
  • Analysis of current complement inhibitors and pipeline candidates.
  • Focus on immunomodulatory approaches for inflammatory conditions.

Main Results:

  • The complement system is a validated target for early intervention in inflammatory diseases.
  • The first complement inhibitors have been approved, with more in development.
  • A variety of complement-mediated pathologies exist, requiring diverse therapeutic approaches.

Conclusions:

  • Targeting the complement system represents a significant advance in treating inflammatory diseases.
  • Ongoing research is yielding promising complement inhibitors for clinical use.
  • A multifaceted therapeutic arsenal is needed to address the spectrum of complement-related disorders.